Skip to main contentAI and Advanced
/
JUBLPHARMA · NSEMarket ticker unavailable · configure an authorised index feed
JU
NSE · Equity shares · Biotechnology & Drugs0.00 · 0.00%
Jubilant Pharmova JUBLPHARMA
NSE:INR 1,005
BSE:INR 927.25
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for JUBLPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,005
Day rangeINR 977.5 — INR 1,010
52-week rangeINR 786.05 — INR 1,184.8
Volume1.54 L
Market cap14,775.74
P/E32.47
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)8,279.6
Net Income (INR Cr)398.5
Rev Growth (5 Year %)6.31
EPS Growth (5 Year %)-7
P/E Ratio32.47
Book Value188.75
EPS27.49
Price/BV5.32Computed
Research path: Interpret Jubilant Pharmova's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
JUBLPHARMAJubilant Pharmova1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 15,522.7 | 12,756.4 | 11,548.5 |
| Accumulated Depreciation Total | -2,197.2 | -1,787.6 | -1,997.2 |
| Cash Equivalents | 19.5 | 19.6 | 50.7 |
| Other Liabilities Total | 2,337.6 | 1,792.2 | 662.7 |
| Accrued Expenses | 445.9 | 321.2 | 265.9 |
| Long Term Debt | 2,971.7 | 2,150.3 | 3,167.1 |
| Common Stock Total | 15.8 | 15.8 | 15.9 |
| Other Equity Total | 1,461.9 | 916.4 | 853.1 |
| Other Current Assets Total | 20.8 | 83.7 | 256.5 |
| Prepaid Expenses | 104.1 | 105 | 91 |
| Total Assets | 15,522.7 | 12,756.4 | 11,548.5 |
| Current Portof LT Debt/Capital Leases | 152.3 | 123.2 | 102.6 |
| Cash | 1,245.7 | 1,066.6 | 903.2 |
| Total Equity | 7,092.8 | 6,254.9 | 5,433.9 |
| Long Term Investments | 68.5 | 49.5 | 42.2 |
| Retained Earnings(Accumulated Deficit) | 5,615.1 | 5,322.7 | 4,565 |
| Total Common Shares Outstanding | 15.84 | 15.84 | 15.84 |
| Property/Plant/Equipment Total-Gross | 9,100.5 | 6,955.8 | 5,684.3 |
| Tangible Book Valueper Share Common Eq | 188.75 | 165.2 | 121.67 |
| Goodwill Net | 2,826.1 | 2,541 | 2,463.9 |
| Total Liabilities | 8,429.9 | 6,501.5 | 6,114.6 |
| Total Debt | 3,614.7 | 2,731 | 3,664 |
| Cashand Short Term Investments | 1,265.2 | 1,086.2 | 953.9 |
| Total Receivables Net | 1,464.9 | 1,153.7 | 1,270.9 |
| Notes Payable/Short Term Debt | 162.5 | 219 | 196.5 |
| Deferred Income Tax | 250.7 | 172.2 | 210.8 |
| Accounts Receivable-Trade Net | 1,175 | 1,005.3 | 1,014.3 |
| Property/Plant/Equipment Total-Net | 6,903.3 | 5,168.2 | 3,687.1 |
| Minority Interest | 2.8 | -16.3 | -12.8 |
| Total Current Liabilities | 2,538.9 | 2,164.6 | 1,889 |
| Total Inventory | 1,254.3 | 1,148.6 | 1,303.8 |
| Accounts Payable | 1,234.1 | 1,004.8 | 856.3 |
| Other Currentliabilities Total | 544.1 | 496.4 | 467.7 |
| Total Long Term Debt | 3,299.9 | 2,388.8 | 3,364.9 |
| Intangibles Net | 1,276.6 | 1,096.7 | 1,043.3 |
| Other Long Term Assets Total | 292.4 | 286.7 | 260.4 |
| Note Receivable-Long Term | 46.5 | 37.1 | 175.5 |
| Total Current Assets | 4,109.3 | 3,577.2 | 3,876.1 |
| Capital Lease Obligations | 328.2 | 238.5 | 197.8 |
| Treasury Stock-Common | Not available | Not available | -0.1 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %5.02
Margins
Operating Margin 12m9.18
Operating Margin 5y Avg9.47
Net Profit Margin 12m4.8
Net Profit Margin 5y4.78
Yield
Dividend Yield %0.54
Valuation
Price to Sale Ratio1.78
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk25.77
Analyst consensus
ConsensusBuy
Consensus score2.25
Analyst opinions4
Strong Sell count0
Sell count1
Hold count0
Buy count2
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 47.68%
- FII
- 15.87%
- MF
- 8.99%
- Other
- 27.46%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Tax Setback for Jubilant Generics as Department Orders Rs 107.89 Cr Adjustment - Medical DialoguesMarket news · 29 May 2026, 10:45 am
Tax Setback for Jubilant Generics as Department Orders Rs 107.89 Cr Adjustment Medical Dialogues
Ashish Mukkirwar appointed CFO of Jubilant Pharmova - Indian Pharma PostMarket news · 27 May 2026, 1:30 pm
Ashish Mukkirwar appointed CFO of Jubilant Pharmova Indian Pharma Post
Jubilant Pharmova re-appoints MDs for three years - scanx.tradeMarket news · 27 May 2026, 12:30 pm
Jubilant Pharmova re-appoints MDs for three years scanx.trade
Jubilant Pharmova Ltd is Rated Sell - Markets MojoMarket news · 27 May 2026, 10:45 am
Jubilant Pharmova Ltd is Rated Sell Markets Mojo
Jubilant Pharmo Consolidated March 2026 Net Sales at Rs 2,290.00 crore, up 18.73% Y-o-Y - Moneycontrol.comMarket news · 26 May 2026, 1:00 pm
Jubilant Pharmo Consolidated March 2026 Net Sales at Rs 2,290.00 crore, up 18.73% Y-o-Y Moneycontrol.com
Jubilant Pharmo Standalone March 2026 Net Sales at Rs 70.30 crore, down 67.65% Y-o-Y - Moneycontrol.comMarket news · 26 May 2026, 12:30 pm
Jubilant Pharmo Standalone March 2026 Net Sales at Rs 70.30 crore, down 67.65% Y-o-Y Moneycontrol.com
Corporate actions
Events
- annual General MeetingAGM
- annual General MeetingPOM
- board Meetings(Revised)
- board MeetingsQuarterly Results
- dividendRs.5.0000 per share(500%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Jubilant Pharmova
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- JUBLPHARMA
- BSE Code
- 530019
Questions
Stock FAQ
What is the symbol and ISIN of Jubilant Pharmova?
Jubilant Pharmova has the symbol JUBLPHARMA and ISIN - INE700A01033.
What is the current price of Jubilant Pharmova?
Jubilant Pharmova is currently trading at INR 1,005.00.
What are the year high and year low of Jubilant Pharmova?
Jubilant Pharmova has a year high of INR 1,184.80 and a year low of INR 786.05.
What is the market capitalization of Jubilant Pharmova?
Jubilant Pharmova has a market capitalization of INR 14,775.74 crore.
What is the P/E ratio of Jubilant Pharmova?
Jubilant Pharmova has a P/E ratio of 32.47.
What is the dividend yield of Jubilant Pharmova?
Jubilant Pharmova has a dividend yield of 0.54%.
How is the financial performance of Jubilant Pharmova based on revenue, net income, and EPS?
Jubilant Pharmova has revenue of INR 8,279.60 crore, net income of INR 398.50 crore, and EPS of INR 27.39.
What is the book value of Jubilant Pharmova?
Jubilant Pharmova has a book value of INR 188.75.
What is the debt-to-equity ratio of Jubilant Pharmova?
Jubilant Pharmova has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Jubilant Pharmova?
Jubilant Pharmova has a price-to-book ratio of 5.32 and a price-to-sales ratio of 1.78.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.